The treatment and understanding of ANCA associated vasculitis (AAV) continues to evolve. I’m in the middle of watching an AAV session at the American College of Rheumatology 2022 meeting and felt inspired to share some newer Rituximab related insights. Firstly, as of September 2022, Rituximab now has an unrestricted listing under…
Read MoreThe ANZVASC patient webinars from 2021 and 2022 are now online and free to access. Topics covered in the 2022 session are listed below. I was fortunate to be involved with the fantastic group of speakers and have summarised my take on “new and emerging treatment for large vessel vasculitis” in…
Read More
ANZVASC is hosting its annual 2 hour patient webinar on 4th June 2022 at 11am AEST. Talks will be focused on new/emerging therapies in vasculitis, bone health, infections and vaccinations, and psychological support for those with vasculitis. It should be another outstanding session. For those who are interested, the 2021 patient…
Read More
A few times a year we receive a call from our cardiothoracic colleagues to assist with patients who have inflammation in the thoracic aorta. These patients have usually undergone surgery to repair aortic widening (aneurysm). It is not know if these patients are at higher risk of complications after the operation…
Read More
This is an exciting new trial for patients with newly diagnosed ANCA vasculitis (AAV). Particularly those with a positive MPO antibody. 140 Japanese patients with new onset AAV were enrolled. All patients were treated with Rituximab. Most of them had an MPO antibody and the average age was 73 years. Half…
Read More
The Australian and New Zealand Vasculitis Society (ANZVASC) is hosting a 2 hour patient webinar at 11am on Saturday May 15th. The program is below and you can register here:
Read More
